Artiva Biotherapeutics Inc
ARTV4.030USD
+0.160+4.13%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
98.92MValor de mercado
PerdaP/L TTM
Mais detalhes de Artiva Biotherapeutics Inc Empresa
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Informações de Artiva Biotherapeutics Inc
Código da empresaARTV
Nome da EmpresaArtiva Biotherapeutics Inc
Data de listagemJul 19, 2024
CEOAslan (Fred)
Número de funcionários89
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 19
Endereço5505 Morehouse Drive
CidadeSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Telefone18582674467
Sitehttps://www.artivabio.com/
Código da empresaARTV
Data de listagemJul 19, 2024
CEOAslan (Fred)
Executivos da empresa Artiva Biotherapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
106.84K
+67253.00%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-1341.00%
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
106.84K
+67253.00%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-1341.00%
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Detalhamento da receita
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qua, 17 de dez
Atualizado em: qua, 17 de dez
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RA Capital Management, LP
40.14%
GC Biopharma Corp
18.61%
5AM Ventures
9.59%
VR Adviser, LLC
6.56%
VenBio Partners LLC
4.68%
Outro
20.42%
Investidores
Investidores
Proporção
RA Capital Management, LP
40.14%
GC Biopharma Corp
18.61%
5AM Ventures
9.59%
VR Adviser, LLC
6.56%
VenBio Partners LLC
4.68%
Outro
20.42%
Tipos de investidores
Investidores
Proporção
Venture Capital
56.48%
Corporation
18.61%
Hedge Fund
5.50%
Individual Investor
5.43%
Private Equity
4.68%
Investment Advisor/Hedge Fund
3.61%
Investment Advisor
2.85%
Research Firm
1.28%
Outro
1.56%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
113
18.19M
82.07%
+1.82K
2025Q3
113
18.19M
82.47%
-356.42K
2025Q2
106
18.54M
87.44%
-2.45M
2025Q1
93
21.00M
87.08%
-218.92K
2024Q4
86
21.21M
85.45%
+459.05K
2024Q3
67
20.75M
65.99%
+4.72M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RA Capital Management, LP
9.85M
40.14%
--
--
Sep 30, 2025
GC Biopharma Corp
4.57M
18.61%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.59%
--
--
Sep 30, 2025
VR Adviser, LLC
1.61M
6.56%
--
--
Sep 30, 2025
VenBio Partners LLC
1.15M
4.68%
--
--
Sep 30, 2025
Aslan (Fred M.D.)
805.78K
3.28%
+797.75K
+9937.16%
Dec 15, 2025
Citadel Advisors LLC
798.40K
3.25%
+644.66K
+419.32%
Sep 30, 2025
Franklin Advisers, Inc.
520.33K
2.12%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
280.30K
1.14%
-176.75K
-38.67%
Sep 30, 2025
Millennium Management LLC
262.16K
1.07%
-64.91K
-19.85%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Ver Mais
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Biotechnology ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
iShares Micro-Cap ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
